Developing comprehensive screening for early-stage cancer is the key to saving the most lives.
Although multi-cancer early detection (MCED) tests are still being researched and lack FDA approval, several are commercially available for consumers who are willing to pay out-of-pocket. Individuals can ask their doctor to order the Galleri blood test from Grail, or they can opt for a whole-body MRI from companies like Prenuvo or Ezra, which often cost $2,000 or more.
Soon, consumers will have another — and rather unique—way to screen for multiple types of cancer.
SpotitEarly, a biotech company that’s a part of Startup Battlefield at TechCrunch Disrupt 2025, is developing an at
Continue Reading on TechCrunch
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.